Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing peptide therapeutics for cancer, announced its participation in the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum, scheduled for October 8-9, 2024. Company management will engage in one-on-one meetings with investors during the conference.
Sapience Therapeutics' Pipeline
Sapience Therapeutics is dedicated to creating peptide therapeutics that address oncogenic and immune dysregulation, key drivers of cancer progression. The company utilizes its in-house discovery capabilities to develop a pipeline of therapeutic candidates called SPEARs™ (Stabilized Peptides Engineered Against Regulation). These SPEARs™ disrupt intracellular protein-protein interactions, enabling the targeting of traditionally undruggable transcription factors. Additionally, Sapience is developing SPARCs™ (Stabilized Peptides Against Receptors on Cancer), a new class of molecules designed to direct cargo, such as α-particles, to cancer cells.
Clinical Programs
Sapience is currently advancing two clinical programs through Phase 2 studies. ST316, a first-in-class antagonist of β-catenin, is one of the lead programs. The other is ST101, a first-in-class antagonist of C/EBPβ. These programs represent novel approaches to targeting key pathways involved in cancer development and progression.
